Overview of Sanmigran

Property	Description
Active ingredient	Pizotifen (Pizotifen malate)
Form	Tablets, Liquid oral solution (syrup)
Pharmacological class	Serotonin Antagonist and Antihistamine
General purpose	Prophylactic (preventative) headache management
Origin	Synthetic organic compound

What Type of Medicine is Sanmigran (Pizotifen)?

Sanmigran is a prescription-only medicine whose active ingredient is Pizotifen, primarily classified as a serotonin antagonist and antihistamine. It functions as a prophylactic agent intended for the long-term management of severe, periodic vascular headaches. Pizotifen is a synthetic substance derived from the tricyclic benzocycloheptene chemical group, meaning it is entirely produced through chemical synthesis and not from natural sources. This substance has a recognized role in preventative therapy; Pizotifen is an established treatment for migraine prophylaxis, primarily based on its serotonin antagonist action. This means the medicine is specifically recognized for its effectiveness in helping to make headaches less frequent.

Composition, Form, and General Purpose

The medicinal product Sanmigran is a single-ingredient product, containing only Pizotifen, typically prepared as the malate salt. Pizotifen malate is prepared for patients in a solid oral form, commonly a tablet, and also as a liquid oral solution or syrup. The availability of both the tablet and liquid forms is a key feature, allowing greater flexibility, especially when treating specific patient groups like children. Both forms are designed for the oral route of administration.

Sanmigran operates by blocking the effects of key natural chemical messengers, specifically serotonin and histamine, which are involved in triggering vascular changes. By targeting these systems, it helps to stabilize blood vessels in the head. This leads to the general benefit of prophylactic management: reducing the overall frequency and intensity of headache episodes over time.

Regulatory References

NICE research recommendation on Pizotifen

What side effects are possible with Sanmigran?

Possible side effects and safety information

The safety profile of Pizotifen (Sanmigran) is formally documented in government regulatory documents, which classify adverse reactions according to frequency and affected organ system. The most commonly reported effects are associated with central nervous system activity and metabolic changes.

Frequency of Adverse Reactions

The following frequency classifications are used to describe how often side effects may appear, based on available regulatory data:

Very Common (may affect more than 1 in 10 people): Increased appetite, resulting in weight gain.
Common (may affect up to 1 in 10 people): Sedation (drowsiness), dizziness, fatigue, dry mouth, and nausea.
Rare (may affect up to 1 in 1,000 people): Certain psychiatric disorders (e.g., anxiety, hallucinations) and hypersensitivity reactions (e.g., rash).

System-Organ Classes and Safety Notes

The official labeling organizes adverse reactions into categories such as Metabolism and nutrition disorders, Nervous system disorders, and Gastrointestinal disorders. Rare post-marketing reports include cases of Hepatic injury and Hepatitis, the frequency of which cannot be estimated from the available data.

Time-Related Patterns: Sedation and drowsiness are officially noted to be more pronounced at the beginning of treatment and may lessen with continued use.

Special Population Safety: Official documents require caution for use in patients with a history of hepatic or renal impairment, and in those with pre-existing conditions like angle-closure glaucoma or conditions causing urinary retention. Caution is also warranted for use in the elderly and children under two years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation describes the overdose profile of Sanmigran (Pizotifen) based on documented clinical signs, severe outcomes, and mandated emergency actions.

Documented Manifestations and Severe Outcomes

Overdose may present with Central Nervous System (CNS) effects such as drowsiness, confusion, dizziness, and fever (pyrexia). Other listed manifestations involve the Cardiovascular System (tachycardia, hypotension) and Anticholinergic System (dry mouth, vomiting). Severe outcomes officially documented include convulsions, coma, and respiratory paralysis, highlighting the life-threatening nature of the event.

Required Emergency Actions

Immediate medical help is required for suspected overdose, even in the absence of symptoms. Regulatory guidance directs contacting a healthcare practitioner, hospital emergency department, or a regional Poison Control Centre immediately. Excitatory states and convulsions are specifically noted as potential manifestations in overdose cases involving children.

Management and Monitoring

No specific antidote is noted in the official regulatory texts. Management involves supportive and symptomatic treatment, including the administration of activated charcoal and measures like diuresis. Monitoring of the cardiovascular and respiratory systems, including ECG monitoring (with attention to QRS and QT intervals), is indicated. A specific caution is noted that the use of adrenaline (epinephrine) to correct severe hypotension may produce paradoxical effects.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile through explicitly listed manifestations that can progress to severe outcomes, mandating the action to seek immediate medical help. This guidance informs the supportive management strategy, which is required due to the officially noted absence of a specific antidote.

Therapeutic Uses of Sanmigran

What Sanmigran Treats: Main Uses and Benefits

Sanmigran (Pizotifen) is applied in addressing the prophylactic management of headache disorders.

This medication is generally used across conditions involving episodic or fluctuating manifestations of severe, vascular-type headaches. It is considered relevant for use in preventing classical migraine, common migraine, and cluster headache. Its application is relevant when supportive symptom management is appropriate for prevention in patient groups including adults and children.

The medication is used for managing the frequency and severity of these episodic headache attacks. By supporting the patient during difficult episodes by easing distress, Sanmigran may contribute to enhancing comfort during periods of heightened symptoms. This may help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability.

“The medication is commonly used to help with long-term preventative therapy for recurrent, severe headaches, assisting with easing the overall symptom burden.”

Quick Fact: Supportive Relief for Recurrent Headaches

Sanmigran plays a role in managing the frequency of headache episodes. It is a preventative measure for adults and children experiencing recurrent, debilitating vascular head pain. It is applied when supportive symptom management is appropriate for prevention.

Eligibility and Restrictions for Use

Official Population Eligibility for Sanmigran (Pizotifen)

Official regulatory documentation defines eligibility for Sanmigran primarily through specific contraindications and restrictions based on patient population, age, and pre-existing medical conditions.

Eligibility Status	Population/Condition
Contraindicated	Patients with known hypersensitivity to pizotifen or any component.
	Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.
	Patients with gastrointestinal obstruction (e.g., pyloroduodenal obstruction).
	Children younger than 12 years of age (in certain national guidelines).
Restricted / Caution	Patients with renal impairment or hepatic impairment (dosage adjustment may be necessary).
	Patients with narrow-angle glaucoma or a predisposition to urinary retention.
	Patients with a history of epilepsy or seizures.

Age and Physiological States

Sanmigran is approved for use in adults and for headache management in older children and adolescents, though some authorities advise caution for those over 65 due to more frequent organ dysfunction. Use in pregnant women is generally not established for safety, and the medicine is not recommended for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Medicinal product categories with documented interactions:

Monoamine Oxidase Inhibitors (MAOIs)
Central Nervous System (CNS) Agents
Adrenergic Neurone Blockers
Drugs which exclusively undergo Glucuronidation

Interaction-related restrictions:

Contraindicated Combination: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited.
Timing Requirement: A 14-day separation period is required, meaning Pizotifen must not be started within 14 days of discontinuing MAOI therapy.

Interaction Classifications

Official interaction statements:

The central depressant effects of CNS agents, including sedatives, hypnotics, and psychotherapeutic agents, may be enhanced. This includes alcohol, and regulatory documents state that tolerance to alcohol may be reduced.
Pizotifen antagonizes the hypotensive effect of adrenergic neurone blockers, potentially reducing the blood pressure-lowering action of these medications.
A pharmacokinetic interaction potential is identified: because Pizotifen is primarily metabolized by N-glucuronidation, an increased plasma concentration of Pizotifen cannot be ruled out when taken with other drugs that rely exclusively on glucuronidation.
Co-administration may lead to the reduced efficacy of the medicine Cisapride.

Connection to the overall interaction profile: The regulatory documents structure the product’s interaction profile around a strict prohibition on co-administering MAOIs and caution regarding pharmacodynamic reinforcement with CNS depressants. The profile also includes the possibility of reduced efficacy for specific co-administered drugs and an inherent pharmacokinetic interaction risk tied to the drug’s primary metabolic pathway.

Mechanism of Action

Pizotifen engages multiple biogenic amine receptors, mediating inhibitory effects that modulate pathways associated with specific physiological responses.

Serotonin and Tryptamine Pathway Modulation

Pizotifen is an antagonist at several serotonin receptors, primarily the 5- HT2A and 5- HT2C subtypes. This mechanism modifies early molecular steps that shape systemic physiological outcomes by inhibiting signaling sequences mediated by serotonin. Additionally, the drug inhibits the re-uptake of serotonin by blood platelets, a process that influences the regulation of blood vessel tone.

Histamine and Kinin Signaling Effects

The drug engages mechanisms that influence the regulation of processes by mediating an antagonist effect on the histamine H1 receptor. This action, alongside its anti-kinin properties, influences systems where targeted pathway adjustment is required. The resulting physiological effect involves the suppression of histamine-mediated actions on vascular tissue.

Central Nervous System Receptor Engagement

Pizotifen affects systems where specific transmitters or mediators dominate. Its interactions in the central nervous system include modulation of alpha-adrenergic and muscarinic acetylcholine receptors, influencing central signaling patterns.

Dosage and Administration Information

How to Use Sanmigran: Administration Guidelines

Sanmigran, which contains the active ingredient Pizotifen, is a preventative medication administered strictly via the oral route. It is available for use as both tablets and a liquid oral solution (syrup), allowing for flexible application, particularly in pediatric care.

Standard Dosing and Scheduling

Treatment is initiated using a low starting dose, typically 0.5 mg daily. The dose is then progressively adjusted to reach the usual maintenance dose of 1.5 mg daily. The total daily dose can be given either as a single dose or in two or three divided doses.

To minimize potential effects related to administration, the largest dose, or the entire single daily dose, is generally taken at night. The maximum total daily dose for the treatment is 4.5 mg when administered in divided doses. The medicine can be taken with or without food.

Use Over Time and Special Populations

Since Sanmigran is used for prophylaxis, continuous administration for several weeks is required before the full therapeutic response can be assessed. The medicine is not indicated for treating an acute headache attack once symptoms have begun. If the treatment is to be discontinued, the medicine should be withdrawn gradually to ensure proper cessation of therapy.

Specific dosage guidance is provided for pediatric patients (ages 2 to 12), who generally receive up to 1.5 mg daily. Furthermore, caution is advised, and dose adjustment may be necessary for patients with hepatic or renal impairment due to the drug’s metabolism and excretion profile.

Recent Clinical Evidence

Research evidence / Overview of studies for Sanmigran (Pizotifen)

Evidence for Prophylaxis of Migraine

The primary research for Sanmigran was studied for its role in research exploring conditions characterized by migraine. The foundational evidence is built on historical Randomized Controlled Trials (RCTs), with findings that are observed in modern systematic reviews and meta-analyses. Research examined the medicine in adults diagnosed with common and classical migraine.

Researchers measured patient-reported outcomes describing perceived discomfort, episodic changes, attack frequency, headache severity, and the documentation of acute/rescue medication use. Findings describe patterns observed in the studies where participants receiving Sanmigran reported different outcomes related to attack frequency compared to those receiving a placebo (inactive pill). Due to the age and methodology of the original RCTs, the overall certainty of this evidence remains low when assessed by current scientific standards.

Evidence in Special Populations: Children and Adolescents

Research was evaluated in a special population of children and adolescents with migraine. Studies focused on research exploring short-term symptom changes and included small-scale controlled trials and retrospective observational studies. Findings were mixed across the controlled trials. While some studies monitored how symptoms evolved in the measured number of attacks, other similar trials did not report a significant difference compared to placebo. Overall, the available data for certain groups remain insufficient, and the evidence quality varies across studies.

What is Still Uncertain About Sanmigran Research

Long-term effects are not fully established by controlled trial data, as the majority of reliable clinical evidence was observed in trials with follow-up durations that were limited, typically lasting only 8 to 16 weeks. Furthermore, there is an established need for new, contemporary RCTs to reassess the focus of the medicine in both adults and, particularly, in children and adolescents. These needed studies are required to provide an updated assessment of symptom patterns using current research techniques.

Key Studies & References

Migraine in over 12s: diagnosis and management (NICE Guideline NG128)

Frequently Asked Questions (FAQ)

Common questions about Sanmigran (FAQ)

Q: How quickly can someone expect Sanmigran to start working?

According to official product information, continuous administration is required before the full preventative effect can be assessed. It typically takes several weeks of consistent use to determine the complete therapeutic response of the medicine.

Q: How long does the effect of a Sanmigran dose usually last?

Regulatory documents describe the active ingredient, Pizotifen, as having a relatively long presence in the body. It is eliminated with a half-life of approximately 23 hours. This technical measurement relates to the time required for the amount of active ingredient in the body to decrease by half.

Q: Is Sanmigran considered a long-term treatment option?

The medicine is officially recognized for its role in prophylactic (preventative) management, which involves continuous use over time. However, official reviews of the research indicate that controlled trial data on the true long-term effects is limited.

Q: What's the difference between Sanmigran and other medicines for the same condition?

Official documents classify Sanmigran as an antimigraine drug that works primarily by acting as a powerful serotonin and tryptamine antagonist and a marked antihistamine. This specific classification defines how it differs from other treatments that may operate through different mechanisms.

Q: Are there any serious side effects associated with Sanmigran that I should know about?

Official reports of side effects note that rare post-marketing cases have included instances of Hepatic injury and Hepatitis. Regulatory guidelines state that if clinical evidence of liver issues is observed, treatment discontinuation is warranted.

Q: Does taking Sanmigran affect fertility in men or women?

Preclinical safety data for the active ingredient is noted in official product literature. Official product information is noted to include a warning that the active ingredient is suspected of damaging fertility or the unborn child.

Q: Are there any food or drinks I should avoid when using Sanmigran?

Regulatory documents state the medicine can be taken with or without food. However, official caution is warranted when consuming alcohol because the medicine may reduce alcohol tolerance.

Q: Is Sanmigran an opioid or a controlled substance?

Sanmigran is classified as an Antimigraine preparation (ATC code N02CX01) and is not an opioid. It is designated as a prescription-only medicine (POM) because its effects and the potential for adverse reactions require medical supervision.

Q: Is it safe to use Sanmigran if I have high blood pressure?

High blood pressure itself is not specifically listed as a contraindication. However, the medicine is described in official documents as antagonizing the hypotensive effect of certain medications used to treat high blood pressure (adrenergic neurone blockers).

Q: Is Sanmigran suitable for people who are older than 65?

Regulatory documents state that no different dosage is typically required for older patients. Regulatory documents indicate caution is advised due to the possibility of more frequent organ dysfunction in this age group.

Q: Where does the official information about Sanmigran come from?

Official information for the medicine is compiled in regulatory documents such as the Summary of Product Characteristics (SmPC). This information comes from authoritative national bodies like the EMA, MHRA, and Health Canada.

Q: Why do some people stop using Sanmigran?

Reasons for discontinuation noted in clinical data primarily include the presence of side effects such as weight gain or excessive sedation. Official guidance states that the medicine must be withdrawn gradually if a person stops taking it.

Q: Is Sanmigran known to cause dependency?

The official product label notes that abruptly stopping the medicine may cause withdrawal symptoms, such as depression and anxiety. Furthermore, tolerance to the drug's effects has been reported with prolonged use.

Q: What should I do if I miss a dose of Sanmigran?

Guidance on a missed dose depends on the schedule, but it generally advises against taking the dose if it is too close to the next scheduled time. Official guidelines state that a double dose must not be taken to make up for a missed dose.

Q: Does Sanmigran affect driving or operating machinery?

Regulatory warnings state that the medicine may cause sedation, somnolence, and dizziness. Due to these common effects, official warnings indicate that activities requiring high alertness, such as driving or operating machinery, should be avoided.

Q: Is Sanmigran covered by most insurance plans?

The medicine’s active ingredient is listed on some government pharmaceutical benefits schemes (such as the PBS in Australia). This indicates how official organizations detail subsidized availability in specific regions.

Q: What kind of monitoring is recommended while taking Sanmigran?

Due to the potential for adverse effects, the official label requires caution when the medicine is used in patients with potential hepatic (liver) dysfunction. Treatment must be discontinued if there is clinical evidence of liver abnormality.

Q: What does 'contraindication' mean regarding Sanmigran?

The term contraindication is used in official documentation to describe a specific patient condition or situation (such as taking MAOIs) where the medicine must not be used. This is because the risks of use would outweigh any possible benefit.

Q: Are there long-term health concerns related to Sanmigran use?

While the medicine is for long-term management, official research reviews confirm that long-term effects are not fully established by controlled trials. Rare post-marketing reports of conditions such as hepatic injury are also documented.

Q: What is the drug's safety classification during pregnancy?

Official regulatory documents state that the medicine's safety in pregnant women is not established and is therefore not recommended for use. This classification is based on available data from official sources.

Q: Can Sanmigran be crushed or split?

The medicine is officially available in both a tablet form and a liquid oral solution (syrup). The availability of the liquid form provides an alternative for individuals who may have difficulty swallowing tablets whole.

Q: Is there a patient information leaflet available for Sanmigran online?

Regulatory bodies require a detailed Patient Information Leaflet (PIL) to be supplied with the medication. These leaflets are frequently available online from official drug regulatory websites for patient access.

Q: Why is Sanmigran only available by prescription?

The medicine is designated as a prescription-only medicine (POM) because its therapeutic effects and potential for adverse reactions (such as sedation or glaucoma risk) require medical diagnosis and ongoing supervision.

Q: Does Sanmigran affect mood or cause depression?

Depression is listed as a rare psychiatric disorder side effect in official reports. It is also noted as a symptom that can occur during withdrawal if the medicine is stopped abruptly.

Q: What are the signs of an allergic reaction to Sanmigran?

Official reports list rare signs of an allergic reaction, which include hypersensitivity reactions and face oedema (swelling). Any sign of an allergic reaction should be taken seriously.

Q: What happens if I accidentally take too much Sanmigran?

An overdose may lead to symptoms such as drowsiness, dizziness, confusion, or convulsions. Regulatory documentation describes procedures for managing an overdose, including the potential administration of activated charcoal and monitoring of heart and respiratory function.

How should Sanmigran be stored and disposed of?

Storage and Disposal Requirements for Sanmigran (Pizotifen)

Storage Requirement	Conditions Mandated by Regulatory Labeling
Temperature & Protection	Store at a temperature below 30°C and protect from light and moisture for stability.
Container Rule	Must be kept in the original container/package.
Child Safety	Keep out of the sight and reach of children.

The medicine must be kept in its original packaging at a controlled room temperature to prevent degradation from heat, light, and moisture. Disposal of any unused or expired Sanmigran must be conducted according to local requirements. Official instructions advise against throwing the medicine into household garbage or disposing of it in wastewater.

Sanmigran